Why the study?
Does SCH 31846 effectively inhibit angiotensin-converting enzyme compared to MK 421 in preclinical models?
Population
Preclinical models including rabbit pulmonary ACE in vitro, anesthetized and conscious rats, and dogs
Comparison
SCH 31846 administered intravenously, orally, or… vs MK 421 (and its diacid)
Design
Preclinical
Authors
Loading...
SCH 31846 shows potent preclinical ACE inhibition; leaves open clinical translation and comparative efficacy versus MK 421.
Does SCH 31846 effectively inhibit angiotensin-converting enzyme compared to MK 421 in preclinical models?
SCH 31846 is a potent, specific, non-sulfhydryl ACE inhibitor with rapid onset and long duration of action in preclinical models.
Sybertz et al. (1983) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: